 BEIJING--BUSINESS WIRE--Sinovac Biotech Ltd. NASDAQ: SVA Sinovac or the Company, a leading provider of biopharmaceutical products in China, announced The Lancet Infectious Diseases published results from the Phase III clinical trials of an inactivated COVID-19 vaccine developed by SINOVAC, also known as CoronaVac, in healthy children and adolescents aged 3-17 in China. The double-blind, randomized, placebo-controlled study evaluated the safety, tolerability and immunogenicity of Cor 